Estradiol valerate/dienogest - Bayer Schering Pharma

Drug Profile

Estradiol valerate/dienogest - Bayer Schering Pharma

Alternative Names: BAY 865027; Dienogest/estradiol valerate - Bayer Schering Pharma; DUB Qlaira; DUB-OC; E2/DNG - Bayer Schering Pharma; Natazia; Qlaira; SH T00658; SH T00658ID; SH T00658K; SH T00658L

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
  • Class Estradiol congeners; Estrenes; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Contraception; Metrorrhagia

Most Recent Events

  • 01 Jun 2015 Bayer completes a phase III trial in Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (NCT01638923)
  • 02 Mar 2015 Estradiol valerate/dienogest is still in a phase III trial for Metrorrhagia in China, Philippines, Russia, Singapore, Taiwan and Thailand (PO)
  • 16 Dec 2014 Bayer HealthCare Pharmaceuticals completes a phase III trial in Contraception/Pregnancy (Prevention) (In volunteers) in China, Hong Kong, India, Taiwan and Thailand (NCT01638910)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top